revenu million
valu usd unless otherwis note
view pipelin and/or bd remain key growth base
busi remain steadi expect season top-lin headwind
off-set one-tim ep benefit believ new ceo day
articul well framework futur busi strategi someth
believ help improv investor confid major upcom
catalyst share continu look inexpens us like near
valuat floor given optim lt hiv foundat increas pt
model updat
initi hint strateg direct priorit inflamm
car-t carv though remain earli day new ceo oday
hope offer hint key area emphasi clear
priorit bd dividend share buyback use capit
well-receiv though believ express predilect
earlier-stag bolt-on leverag exist expertis
identifi add valu opportun may disappoint hope
transform deal notabl view
palpabl increas enthusiasm filgotinib compani view
cornerston vision build inflamm
plan separ kite busi unit still
like high scienc long-term opportun deliveri infrastructur
improv cell therapi move earlier line believ
distanc improv platform agil well investor
hiv perform gener expect biktarvi strength
offset cannib season soft across
franchis biktarvi sale well exceed consensu beat
even high optimist estimate offset weak across
rest hiv franchis includ truvada stribild odefsey
due cannib dynam continu view
favor given biktarvi long exclus period competit
advantag well expect one-tim season factor
inventori payer mix medium-term hiv drug price dynam
remain focu given competit entri medicar protect class
propos though appear confid see limit medium-
theoret cushion resist lower efficaci sicker pt pregnanc
risk like high discount gild cocktail anyway
potenti except prep truvada generic
exclud one-tim factor overal busi oper track
gener line limit pipelin updat lower one-
consensu continu page
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
bloomberg capit market estim upside/downside/target
base case assum reason sustain hiv
modest price increas convert mani patient
biktarvi meaning price declin hcv
price share stabil worsen volum
beyond gradual strong out-year yescarta uptak
po follow-on indic po
filgotinib ra ibd price target deriv
dcf analysi discount rate termin
growth rate post-taf gener
better expect hcv share retent long-term hiv
price power despit gener entrant success filgotinib
nash product higher revenu car-t product
would lead upsid estim scenario
potenti dcf base valuat would
competit impact hiv hcv franchis greater
expect price pressur slower yescarta uptak failur
expand label failur filgotinib would lead downsid
estim scenario potenti dcf valuat
would
believ biktarvi strong profil robust launch
along favor demograph price dynam
underpin good hiv franchis sustain
nearer-term competit threat overblown expect
maintain strong foundat valuat though
expect continu hcv declin increas competit
recent disrupt entrant share price stabil
provid predict sustain patient
volum still contribut meaning
cash flow next decad expans cellular
therapi solid initi uptak yescarta help establish
core infrastructur addit invest new
modal help provid durabl out-year revenu
growth maintain lead edg new therapeut area
could built upon futur also see filgotinib
potenti blockbust pipelin overal expect
success pipelin diversif cellular therapi
inflamm help drive share appreci
power demograph hiv predict hcv
share price sustain volum
pipelin program filgotinib aggress expans
cellular therapi franchis provid new foundat futur
risk patent expiri competit may impact
lt hiv revenu hcv competitor could compress
pricing/shar near term unknown remain nash
competit unanticip shift eu
potenti catalyst submiss eu ra
potenti fda approv descovi prep
data atla combo nash trial
expect lower ep rest despit hiv bounceback letairis/ranexa
generic tax rate normal hcv inflat order
pattern though still see rel stabil annual basi accommod
growth bd/pipelin advanc unchang guidanc reflect overal stabil
pipelin front filgotinib regulatori updat limit given still await
regulatori feedback continu monitor oral ph potenti
hbv oncolog potenti approach rel currently-market
producteventtimelinedescovypotenti fda approv ph ii sjogren syndrom ph ii lupu eu phase studi psoriat phase studi ankylos select studi enrol divers studi ph iii studi diabet kidney week interim data selonsertib selonsertib combin data atla phase studi selonsertib and/or and/or patient advanc fibrosi due fxr complet enrol ph iii studi ph ii studi cutan lupu ph ii studi sjogren enrol ph ii studi ebola ph studi hiv agonist data ph ii hbv inhibitor initi ph ii studi data cohort evalu earli steroid initi ph ii combin studi rituxan revlimid phase combin studi atezolizumab phase combin studi rituximab lenalidomid enrol ph iii studi dlbcl ph ii studi indol nhl data phase combin studi agonist enrol phase studi high risk dlbcl phase result phase data phase registr phase studi pediatr registr ph ii studi mcl enrol pivot ph ii adult phase phase studi cll fda regulatori approv r/r mage enrol phase mage solid tumor bladder urotheli non small cell allogen -t initi clinic studi allogen nunuc data ph ii capsid inhibitor data ph ib studi exhibit pipelin
pipelinedrug/targetindicationstatusbiktarvyhivmarketedhivmarketedprepphas iiirheumatoid arthritisphas iiicrohn diseasephas iiiulcer colitisphas iiipsoriat arthriti ankylos spondyl sjogren syndrom lupu uveitisphas r/r dlbcl pmbcl tfl eu dlbcl iiiindol nhl iidlbcl mab combo iir/r mcl iiadult pediatr cll inashphas iipbcphas iipscphas iifirsocostat nashphas iisjogren syndromephas iicutan lupu erythematosusphas iitirabrutinib btk b-cell malignanciesphas nuc ebolaphas iipresatovir fusion inhibitor respiratori syncyti viru rsv phase nunuc hivphas agonist hbvphase bet solid tumorsphas agonist hiv curephas bnab hivphas capsid inhibitor hivphas mage tumorphas head neck cancerphas gen hematolog malignanciesphas inhibitor ibdphas oral hbvphase head neck cancerpreclin ind allogen -t aallogen gen hematolog malignanciespreclinicalkrassolid tumorpreclinicalhbv epigenet modulatorhbvpreclinicalneoantigenssolid anti-bcma mmdeprioritizeddescovi f/taf filgotinib axi-cel exhibit incom statement
million except per share antivir hcv harvoni/auth unit epclusa/auth unit unit vosevi- unit states- europe- international- total hiv genvoya unit unit unit unit unit unit descovi unit odefsey unit international- biktarvi unit antivir includ vemlidi unit product includ filgotinib prob-adjust nash asset prob-adjust yescarta total product royalti contract total revenu cost research sell gener total oper incom interest interest incom net pre-tax incom tax net net loss attribut non-controlling net incom earn per share outstand share outstand biotechnolog
price target deriv via dcf analysi discount rate termin
growth rate post-taf gener price target support outperform rate
risk rate price target
risk includ gener hiv entrant competit hcv price pressur commerci
scientif complex cellular car-t therapi efficaci safeti risk pipelin
product filgotinib
gilead leader develop market anti-infect drug approv
product treatment hiv/aid hepat hepat pulmonolog diseas
gilead develop pipelin antivir liver diseas inflamm cellular therapi
oncolog gilead extens world-wide sale market infrastructur
